← All indications
COVID-19
A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. A coronavirus, SARS-CoV-2 VIRUS, in the genus BETACORONAVIRUS is the causative agent.
Subtype terms (1)
More specific conditions that are subtypes of COVID-19 in the MeSH hierarchy.
- Post-Acute COVID-19 Syndrome
33 drugs (18 approved, 15 experimental)
Drugs by status
Approved for this indication (32)
- recombinant sars-cov-2 vaccine
- reduning
- zf2001
- nirmatrelvir
- covax-19
- chadox1
- janssen SARS-CoV2 vaccine
- covid19 recombinant spike protein
- remdesivir
- bivalent bnt162b2
- mvc-cov1901
- mrna-1273
- bamlanivimab
- covid-19 vaccine (vero cells)
- delns1-2019-ncov-rbd-opt1
- casirivimab
- covid-19 mrna vaccine
- ad5-ncov
- bnt162b2
- covid-19 vaccine, mrna
- coronavac
- ly3819253
- imdevimab
- cilgavimab
- COVID-19 Vaccine, Adjuvanted
- sotrovimab
- inactivated SARS-Cov-2 vaccine
- inactivated covid-19 vaccine
- ad5-ncov vaccine
- sars-cov-2 ad5
- +2 more
Phase 4 trials (140)
- imatinib
- sodium chloride
- cefotaxime
- darunavir
- pneumococcal 13-valent conjugate vaccine
- hepatitis a vaccine, inactivated
- cod liver oil
- acetylcysteine
- testosterone
- tetrandrine
- daclatasvir
- neostigmine
- blood plasma
- vitamin d3
- zinc sulfate
- urea
- hydrogen peroxide
- retinoic acid
- echinacea
- silymarin
- nitazoxanide
- fluoxetine
- ravulizumab-cwvz
- sars-cov-2 rs
- levofloxacin
- sodium bicarbonate
- nintedanib
- anacaulase
- sulodexide
- cyclosporine
- +110 more
Phase 3 trials (381)
- bardoxolone
- dociparstat
- colistin
- brii-196
- carvacrol
- epivaccorona
- cannabidiol
- Caesalpinia spinosa
- tanshinone iib
- ub-612
- leronlimab
- honey
- nvx-cov2601
- upamostat
- everolimus
- loratadine
- mycobacterium w vaccine
- imidazoquinoline
- amoxicillin
- upadacitinib
- ribavirin
- ptc299
- fb2001
- mad0004j08
- pine bark extract
- chadox1 ncov-19
- clazakizumab
- amantadine
- lansoprazole
- apremilast
- +351 more
Phase 2 trials (426)
- malic acid
- bimervax
- isis 721744
- at-001
- modafinil
- etonogestrel
- centhaquine
- cd40.rbdv vaccin
- dupilumab
- scb-2020s
- vb-201
- Colostrum
- hs-10517
- organicell
- stevia
- phenformin
- dzif-10c
- tcb008
- nangibotide
- trabedersen
- ensifentrine
- tj003234
- sars-cov-2 vlp vaccine-alpha (british) variant - Turkey
- regn10987
- lactobacillus brevis
- av-covid-19
- methylene blue
- secukinumab
- degarelix acetate
- rc19
- +396 more
Phase 1 trials (181)
Other trials (72)
- ubiquinol
- dl-alanine
- ezetimibe
- decidual stromal cells
- beta-hydroxybutyrate
- phr160
- hemp powder
- aprotinin
- lactobacillus reuteri
- atovaquone
- ligilactobacillus salivarius
- acetylcarnitine
- diphenhydramine
- bacillus subtilis
- guduchi ghan vati
- 5-alaphosphate
- luteolin
- magnesium
- prolectin-m
- interferon gamma-1b
- norelgestromin
- borneol
- viracide
- omeprazole
- sa58
- tetracycline
- dantrolene
- ovotransferrin
- tinospora
- vsl #3
- +42 more